Portage Biotech's shares surge after positive preclinical tumor trial data, retail optimism sky-high

From StockTwits: 2025-03-28 01:56:00

Portage Biotech Inc. shares soared in after-hours trading after the company shared promising preclinical data on its tumor growth inhibitor, PORT-7, showing significant tumor growth inhibition in a mesothelioma model. The company reported that when combined with an anti-PD1 antibody, PORT-7 reduced tumor growth by over 90%, with strong immune cell infiltration. Portage is preparing for a first-in-human trial of PORT-7 and advancing dose escalation for PORT-6, an A2A receptor inhibitor. Plans to combine both drugs in the ADPORT-601 trial to enhance immunotherapy effectiveness in solid tumors. Stocktwits sentiment for Portage hit a record high of 100/100.



Read more at StockTwits: Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High